Amir A Jazaeri
M.D. Anderson Cancer Center · University of Virginia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amir A Jazaeri as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05114421 · Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsM.D. Anderson Cancer Center · active not recruiting · High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous Adenocarcinoma · principal investigator
- Ph1/Ph2NCT04019288 · AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerM.D. Anderson Cancer Center · terminated · Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma · principal investigator
- Ph2NCT03610490 · Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaM.D. Anderson Cancer Center · terminated · Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma · principal investigator
- Ph2NCT03531645 · Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaM.D. Anderson Cancer Center · active not recruiting · Malignant Neoplasms of Female Genital Organs · principal investigator
- Ph1NCT03508570 · Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisM.D. Anderson Cancer Center · completed · Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma · principal investigator
- Ph2NCT03449108 · LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasM.D. Anderson Cancer Center · active not recruiting · Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone · principal investigator
- Ph1/Ph2NCT03318900 · T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian CancerM.D. Anderson Cancer Center · completed · COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive · principal investigator
- Ph2NCT03026062 · Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer Center · completed · Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma · principal investigator
- Ph2NCT02884648 · Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look SurgeryM.D. Anderson Cancer Center · active not recruiting · Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer · principal investigator
- Ph1NCT00091273 · Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal CancerUniversity of Virginia · completed · Ovarian Cancer, Primary Peritoneal Cavity Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- SYNTHETIC PEPTIDES IN ADJUVANT VACCINATION IN OVARIAN, PERITONEAL, FALLOPIAN CAM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA · fiscal years 2008 · $15,512 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:36 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).Gynecol Oncol · 2020129 citationsRCR 5.5
- Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.Nat Med · 202565 citationsRCR 12.7
- Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.Gynecol Oncol · 202062 citationsRCR 2.5
- Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial.Sci Rep · 202135 citationsRCR 2.0
- 19 citationsRCR 2.0
- 18 citationsRCR 1.8
- 10 citationsRCR 0.9
- 10 citationsRCR 2.2
- A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.Nat Commun · 20268 citationsRCR 4.0